Japan includes India’s Covaxin in the list of recognized vaccines to facilitate travel from India

Government of Japan includes the indigenously developed and manufactured COVID-19 vaccine Covaxin

April 8, 2022

Japan recognizes India’s Covaxin with effect from 10 April

Japan recognizes India’s COVID-19 vaccine Covaxin manufactured by Bharat Biotech with effect from 10 April to further facilitate travel from India to Japan, said the Indian Embassy in Japan on Thursday.

Taking to Twitter, the Embassy wrote, “Government of Japan includes the indigenously developed and manufactured COVID-19 vaccine Covaxin by Bharat Biotech of India, as one of the recognized vaccines for 1st and 2nd dose with effect from 10 April 2022 to further facilitate travel from India to Japan.”

Government of Japan includes the indigenously developed and manufactured COVID-19 vaccine COVAXIN by Bharat Biotech of India, as one of the recognised vaccines for 1st and 2nd dose with effect from 10 April 2022 to further facilitate travel from India to Japan#IndiaJapanat70 pic.twitter.com/6Rk7iAXLxb

— India in Japanインド大使館 (@IndianEmbTokyo) April 7, 2022

The official handle of Bharat Biotech tweeted the advisory issued by Japan. It said in the tweet, “Japan recognizes India’s COVAXIN to facilitate travel between both the countries.

Japan recognises India’s COVAXIN to facilitate travel between both the countries.https://t.co/ikCzKhYJRc #announcement #BharatBiotech #COVAXIN #japantravel #COVID19 #COVID19Vaccine #indiatojapan pic.twitter.com/WQ24L0wVio

— BharatBiotech (@BharatBiotech) April 8, 2022

Meanwhile, External Affairs Ministry spokesperson Arindam Bagchi had recently said that the supply of COVAXIN through UN procurement agencies will not impact travel by people who have taken the vaccine after World Health Organisation’s suspension.

”I certainly do not think there should be any impact at all on people who have taken COVAXIN. It is a safe vaccine. In terms of their travel, it continues to be recognized under the EUL (emergency use authorization) of WHO,” he said.

In a statement, the WHO had said this suspension is in response to the outcome of the WHO post-Emergency Use Listing (EUL) inspection and the need to conduct process and facility upgrades to address recently identified GMP deficiencies.

PGurus is now on Telegram. Click here to join our channel and stay updated with all the latest news and views

For all the latest updates, download PGurus App.